| OH2 Administered by Intratumoral Injection (NCT05954091) | Binhui Biopharmaceutical Co., Ltd. | 2025-09-01 |
| oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection (NCT05938296) | Binhui Biopharmaceutical Co., Ltd. | 2023-12-19 |
| First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer (NCT05648006) | Binhui Biopharmaceutical Co., Ltd. | 2023-10-17 |
| OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors (NCT07382531) | Binhui Biopharmaceutical Co., Ltd. | 2023-09-07 |
| OH2 Injection in Melanoma (NCT05868707) | Binhui Biopharmaceutical Co., Ltd. | 2023-03-08 |
| Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years (NCT05716347) | Binhui Biopharmaceutical Co., Ltd. | 2022-07-13 |
| OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer (NCT05232136) | Binhui Biopharmaceutical Co., Ltd. | 2022-07-11 |
| OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer (NCT05248789) | Binhui Biopharmaceutical Co., Ltd. | 2022-05-25 |
| OH2 Oncolytic Viral Therapy in Central Nervous System Tumors (NCT05235074) | Binhui Biopharmaceutical Co., Ltd. | 2021-11-16 |
| OH2 Oncolytic Viral Therapy in Pancreatic Cancer (NCT04637698) | Binhui Biopharmaceutical Co., Ltd. | 2021-02-02 |
| OH2 Injection in Combination With HX008 for Melanoma. (NCT04616443) | Binhui Biopharmaceutical Co., Ltd. | 2020-12-01 |
| OH2 Oncolytic Viral Therapy in Solid Tumors (NCT03866525) | Binhui Biopharmaceutical Co., Ltd. | 2019-04-02 |
| OH2 Injection in Solid Tumors (NCT04386967) | Binhui Biopharmaceutical Co., Ltd. | 2018-11-22 |